Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

International Comparisons

The international comparisons section provides a quick guide comparing how products have been assessed by global reimbursement and health technology assessment agencies. The database and reports allow you to discover:

  • What have reviews of your product in other countries reported?
  • What are common criticisms for products in a given drug class?
  • What are successful strategies and common mistakes for health technology assessment submissions?
  • How have reimbursement decisions differed globally and why?
  • Why do some products succeed and others fail?
  • How can you increase the chances of your products success?
  • What can you learn from your competitors submissions?

The fully searchable, online version of the International Comparison database will be launched in the near future. This database includes a simple interface to assess and compare HTA decisions. If you would like to obtain information from the International Comparison database prior to its online launch, please contact us directly.

Global Oncology Reimbursement Recommendation Summary, 13 July 2011 to 28 April 2014
Brand (Generic) Name and Indication pCODR1
(Canada)
PBAC2
(Australia)
TLV3
(Sweden)
NICE4
(United Kingdom)
Adcetris (Brentuximab)
sALCL (second-line)
POSITIVE
(conditional on improved CE)
N/A POSITIVE
[pre-ASCT]
N/A
Adcetris (Brentuximab)
HL (post-ASCT and ASCT-ineligible)
POSITIVE
(conditional on improved CE) [post-ASCT]

NEGATIVE
[ASCT-ineligible]
N/A POSITIVE
[pre-ASCT]
N/A
Afinitor (Everolimus)
pNETs
POSITIVE
(conditional on improved CE)
NEGATIVE N/A N/A
Afinitor (Everolimus)
Breast cancer
POSITIVE
(conditional on improved CE)
POSITIVE N/A NEGATIVE
Alimta (Pemetrexed)
NS-NSCLC
POSITIVE
(conditional on improved CE)
NEGATIVE N/A NEGATIVE
Erbitux (Cetuximab)
Colorectal cancer
NEGATIVE NEGATIVE N/A POSITIVE
Halaven (Eribulin)
Breast cancer
POSITIVE
(conditional on improved CE)
POSITIVE N/A NEGATIVE
Inlyta (Axitinib)
RCC
POSITIVE
(with criteria / conditions)
NEGATIVE
POSITIVE N/A
Jakavi (Ruxolitinib)
Myelofibrosis
POSITIVE
(conditional on improved CE)
NEGATIVE
POSITIVE NEGATIVE
Kadcyla (Trastuzumab)
Breast cancer
POSITIVE
(conditional on improved CE)
NEGATIVE
N/A POSITIVE
Sutent (Sunitinib)
pNETs
POSITIVE
(conditional on improved CE)
POSITIVE N/A N/A
Tafinlar (Dabrafenib)
Melanoma (first-line)
POSITIVE
(conditional on improved CE)
POSITIVE POSITIVE N/A
Treanda (Bendamustine)
Non-HL (first-line and relapse / refractory)
POSITIVE
[first-line]

POSITIVE
(limited population)
[relapse / refractory]
N/A N/A N/A
Treanda (Bendamustine)
CLL (first-line)
POSITIVE
(conditional on improved CE)
N/A N/A POSITIVE
Tykerb (Lapatinib)
Breast cancer
NEGATIVE POSITIVE N/A NEGATIVE
Velcade (Bortezomib)
MM (pre- and post-ASCT
POSITIVE
(conditional on improved CE)
[pre-ASCT]

NEGATIVE
[post-ASCT]
POSITIVE
[pre-ASCT]
N/A POSITIVE
[pre-ASCT]
Votrient5 (Pazopanib)
RCC (first-line)
POSITIVE
(without criteria / conditions)
NEGATIVE POSITIVE POSITIVE
Votrient (Pazopanib)
Soft tissue sarcoma
NEGATIVE POSITIVE N/A N/A
Xalkori5 (Crizotinib)
NSCLC (first- and second-line)
POSITIVE
(conditional on improved CE)
[second-line]

NEGATIVE
[first-line]
N/A POSITIVE
[second-line]
NEGATIVE
[second-line]
Yervoy (Ipilimumab)
Melanoma
POSITIVE
(conditional on improved CE)
POSITIVE N/A POSITIVE
Zelboraf (Vemurafenib)
Melanoma (first- and second-line)
POSITIVE
(conditional on improved CE)
[first-line]

NEGATIVE
[second-line]
N/A NEGATIVE POSITIVE
[first-line]
Zytiga (Abiraterone)
mCRPC
POSITIVE
(conditional on improved CE)
N/A NEGATIVE N/A

Legend: Green text represents positive decisions. Red text indicates negative recommendations due to uncertain clinical benefit and/or uncertain/high cost-effectiveness.
1 www.pcodr.ca      2 www.pbs.gov.au      3 www.tlv.se      4 www.nice.org.uk      5 Represents a re-submission
Abbreviations: ASCT, autologous stem-cell transplant; CE, cost-effectiveness; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MM, multiple myeloma; N/A, not applicable; NICE, national institute for health and care excellence; NSCLC, non-small cell lung cancer; OS, overall survival; PBAC, pharmaceutical benefits advisory committee; pCODR, pan-Canadian oncology drug review; pNETs, pancreatic neuroendocrine tumours; RCC, metastatic renal cell carcinoma; sALCL, systemic anaplastic large cell lymphoma; TLV, dental and pharmaceutical benefits agency.
Note: N/A refers to cancer drug applications either not submitted/reviewed or still pending decision at the time of analysis (13 July 2011 to 28 April 2014).
Disclaimer: The summary of reasons for recommendation are the interpretation of the authors and should not be used as the basis for decision-making without independent confirmation.

Return to Top